Literature DB >> 2083196

Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans.

G C Kaye1, D Mehta, S Wafa, A J Camm.   

Abstract

The acute electrophysiologic effects of an intravenous bolus of ketanserin, a 5HT2 serotonin blocker, were studied in ten patients (four females, six males) during invasive electrophysiology. Following baseline electrophysiologic measurements during sinus rhythm and fixed-rate atrial pacing at 600 ms, a bolus of 0.2 mg/kg ketanserin was given over a 3-minute period. After 30 minutes all measurements were repeated. Systemic blood pressure was measured at regular intervals throughout. During sinus rhythm, there was no significant change in the basic cycle length or in the PA, AH, HV, QRS, QT, and QTc intervals. During atrial pacing there was a nonsignificant increase in the QT interval, from 342 +/- 13 ms to 366 +/- 16 ms, and a significant increase in the QTc interval, from 422 +/- 27 ms to 449 +/- 29 ms (p less than 0.05). There was no reduction in blood pressure. Thus ketanserin produced a significant prolongation of the QTc interval, in the absence of hypokalemia, in humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083196     DOI: 10.1007/BF01856513

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  12 in total

1.  The measurement of the Q-T interval of the electrocardiogram.

Authors:  E LEPESCHKIN; B SURAWICZ
Journal:  Circulation       Date:  1952-09       Impact factor: 29.690

Review 2.  Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.

Authors:  S Saman; F Thandroyen; L H Opie
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

3.  Is ketanserin a D receptor antagonist?

Authors: 
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

4.  Ketanserin--a new antihypertensive agent.

Authors:  A Breckenridge
Journal:  J Hypertens Suppl       Date:  1986-04

5.  Mechanism of the hypotensive effect of ketanserin.

Authors:  J R Fozard
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

Review 6.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.

Authors:  P Vanhoutte; A Amery; W Birkenhäger; A Breckenridge; F Bühler; A Distler; J Dormandy; A Doyle; E Frohlich; L Hansson
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

7.  Sotalol, hypokalaemia, syncope, and torsade de pointes.

Authors:  J K McKibbin; W A Pocock; J B Barlow; R N Millar; I W Obel
Journal:  Br Heart J       Date:  1984-02

8.  Effect of intravenous ketanserin on the human action potential duration at fixed heart rate.

Authors:  A J Drake-Holland; M I Noble; S Pugh; C Mills
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

9.  Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin.

Authors:  M Zehender; T Meinertz; S Hohnloser; A Geibel; J Hartung; K U Seiler; H Just
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778

10.  QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin.

Authors:  A E Aldariz; H Romero; M Baroni; H Baglivo; R J Esper
Journal:  Pacing Clin Electrophysiol       Date:  1986-11       Impact factor: 1.976

View more
  1 in total

1.  Mood disorders, circadian rhythms, melatonin and melatonin agonists.

Authors:  M A Quera Salva; S Hartley
Journal:  J Cent Nerv Syst Dis       Date:  2012-01-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.